
    
      The objective of this study is to evaluate the efficacy and safety of DS-8500a 10 mg and 75
      mg administered orally, once daily, for 28 days, compared with placebo, in Japanese patients
      with Type 2 Diabetes Mellitus in a double-blind, placebo-controlled parallel-group design.
      The primary endpoint is the change in 24-hour weighted mean glucose at day 28 from baseline.
      The safety, pharmacokinetics, and pharmacodynamics of DS-8500a will be evaluated as well.
    
  